A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery

Inclusion Criteria:

- Male or female patients who are 18 years or older

- Patients who are scheduled to undergo an open abdominal surgery (including
laparoscopic-assisted) under general anesthesia or spinal anesthesia that does not
include intrathecal opioids during the operation.

- Post-surgical patients who have been admitted to the PACU and are expected to remain
hospitalized and to have acute post-operative pain requiring parenteral opioids for
at least 48 hours after surgery.

Exclusion Criteria:

- Patients who have taken an opioid for more than 30 consecutive days, at a daily dose
of more than 15 mg of morphine (or equivalent), within the past 3 months prior to
surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg
hydrocodone per tablet).

- Patients with an allergy or hypersensitivity to opioids.

- Female patients who are pregnant or breast-feeding